Celonic Group News Today

Dublin, Feb. 22, 2024 (GLOBE NEWSWIRE) -- The

BASEL, Switzerland, August 03, 2023 / B3C newswire / -- Celonic Group, a Swiss-based Biologics Contract Development and Manufacturing Organization (CDMO), has appointed Dr. Samanta Cimitan as the Chief Executive Officer (CEO) of the Celonic Group, a subsidiary of the independent and privately owned J.RETTENMAIER &am...

/PRNewswire/ -- Advanced Therapy Medicinal Products CDMO Market Size, Share & Trends Analysis Report By Product (Gene Therapy, Cell Therapy, Tissue...

BASEL, Switzerland, June 01, 2022 / B3C newswire / -- Celonic Group, a Swiss-German contract development and manufacturing organization (CDMO), has appointed Dr. Samanta Cimitan as the Chief Business Officer (CBO) of Celonic Group.With more than 20 years’ experience working, teaching, and studying in Life Sciences,...

HEIDELBERG, Germany, March 24, 2022 / B3C newswire / -- The Federal Republic of Germany has announced its decision to sign contracts with Celonic AG and four other partners to secure the long-term supply of vaccines in Germany against Covid-19 and other pandemics. Celonic will provide the capacity and the expertise...

By Syndicated Content By Ludwig Burger (Reuters) -CureVac said its COVID-19 vaccine was 48% effective in the final analysis of its pivotal mass trial, only marginally better than the 47% reported after an initial read-out two weeks ago. The German biotech firm said that efficacy, measured by preventing symptomatic disease, was slightly better at 53% when excluding trial participants older than 60 years, an age group that is by far the most severely affected. CureVac said on June 16 its ...

CureVac fails in pivotal COVID-19 vaccine trial with 47% efficacy FILE PHOTO: A vaccination against the coronavirus disease (COVID-19) from German biotechnology company CureVac is ready to use at the start of a clinical test series in the tropical institute of the university clinic in Tuebingen, Germany, June 22, 2020. REUTERS/Kai Pfaffenbach June 17, 2021 By Ludwig Burger (Reuters) -German biotech CureVac NV said on Wednesday its COVID-19 vaccine was only 47% effective in a late-stage trial,...

DGAP-News: CureVac / Key word(s): Quarter Results/Annual Results CureVac Announces Financial Results and Business Updates for the Fourth Quarter and Full-Year of 2020 15.04.2021 / 13:30 CureVac Announces Financial Results and Business Updates for the Fourth Quarter and Full-Year of 2020 - COVID-19 vaccine candidate: CVnCoV in final stage of clinical development and believed to be well on track to provide data for conditional approval based on EMA rolling submission - Pivotal Phase 2b/3 in Eu...

CureVac Announces Financial Results and Business Updates for the Fourth Quarter and Full-Year of 2020 - COVID-19 vaccine candidate: CVnCoV in final stage of clinical development and believed to be well on track to provide data for conditional approval based on EMA rolling submission - Pivotal Phase 2b/3 in Europe and Latin America fully recruited with over 40,000 participants. Interim analysis for vaccine efficacy expected in Q2 2021 - Phase 2a trial in Peru and Panama amended for addition of s...

By Reuters Staff 2 Min Read FILE PHOTO: A volunteer receives a dose of CureVac vaccine or a placebo during a study by the German biotech firm CureVac as part of a testing for a new vaccine against the coronavirus disease (COVID-19), in Brussels, Belgium March 2, 2021. REUTERS/Yves Herman/File Photo BERLIN (Reuters) - Global supply chains for making COVID-19 vaccines have been disrupted by U.S. restrictions, creating headaches for companies seeking to build production in Europe, according to one...